About Adequan® Canine

The Difference is DMOAD

Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in the dog's synovial joints, and may help to:1

  • Restore joint lubrication
  • Relieve inflammation
  • Renew the building blocks of healthy cartilage

That’s what makes Adequan® Canine different from a supplement or NSAID. It proactively treats the disease and not just the signs of canine osteoarthritis.1

Horse running in stable

Backed by science. Proven over time.

  • The efficacy of Adequan® Canine has been demonstrated in studies and clinical field trials.1
  • Prescribed for over 20 years to help control signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.1
  • It’s been proven to inhibit enzymes that break down cartilage, so joint damage is reduced.1

Rethink OA: Be Proactive.

Drug Med Icon

Be proactive with it: Make mobility a "vital sign" at every visit. Ask the owner about any changes that may indicate onset of a joint problem.

Drug Med Icon

Start with it: Prescribe Adequan® Canine early, at the first clinical signs of degenerative joint disease (DJD) before it progresses to irreversibly damaged cartilage.1

Drug Med Icon

Stay with it: Then, continue to prescribe it as needed to manage the stages of arthritis.

Canine osteoarthritis can progress over time and affect dogs at every stage of life. Don’t wait until the signs become serious and debilitating or until the dog is in its later years to begin looking for OA. Once cartilage wears away completely, it can’t be restored so it’s important to help maintain its use.2

Discover if Adequan® Canine is the right choice.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Do you know there’s also Adequan® for horses?

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.
1. Adequan® Canine Package Insert, Rev 9/2021.
2. 2016 NAVC Proceedings, Osteoarthritis in Dogs and Cats: Novel Therapeutic Advances, M Epstein, DVM, DABVP C/F, CVPP; K Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

CANINE VETERINARY
PROFESSIONAL		 DOG OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up Press Room
ABOUT ADEQUAN® CANINE
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
All trademarks are the property of American Regent, Inc
© 2022, American Regent, Inc.
PP-AC-US-0102 (v6.0) 04/2022